After 33 years Geron could have an approved drug
Imetelstat survives a US clinical hold and a terminated alliance with J&J to score in its pivotal Imerge study.
Ash 2022 movers – Glycomimetics shakes off its sickle cell past
Meanwhile, there was bad blood between cell therapy players and their investors.
Ash 2022 – Orchard gets a Sanfilippo boost
Promising but early data with OTL-201 could see the group compete against the likes of Ultragenyx and Lysogene.
Ash 2022 – toxicity still looms large for Regeneron’s bispecific
Another five treatment-related deaths, despite a dose regimen change, raise questions about whether odronextamab will be able to compete.
Ash 2022 – Astra takes two shots at oral complement inhibition
Meanwhile, Roche sees reasons for optimism with its subcutaneous contender.
Ash 2022 – the sickle cell race hots up
Sangamo emulates Editas, while Crispr/Vertex and Bluebird add weight to their ambitions.
Ash 2022 – Argenx faces Vyvgart questions
As the group looks to expand into immune thrombocytopenia, there are several reasons to be cautious.
An expensive new haemophilia gene therapy hits the US
The approval is good for CSL, and better for Uniqure.
Ash 2022 preview – Novartis has Apellis in its sights
Iptacopan looks as good as Empaveli in PNH, with the added bonus of being oral.
